<DOC>
	<DOCNO>NCT01062620</DOCNO>
	<brief_summary>A dose escalate phase Ia-b clinical trial IGF-1 receptor inhibitor AXL1717 patient advance cancer . The objective study safety pharmacokinetics AXL1717 define appropriate Phase 2 dose study . This first study man . The study design show tumor response .</brief_summary>
	<brief_title>A Dose Escalating Clinical Trial IGF-1 Receptor Inhibitor AXL1717 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>1 . At least 18 year age . 2 . Histologically confirm diagnosis advance solid haematological malignancy amenable standard treatment . 3 . Pharmacological treatment attempt justify 4 . Preserved major organ function , i.e : BLeukocyte count ≥ 3.0 x 109/L BNeutrophil count ≥ 1.5 x 109/L BPlatelet count ≥ 75 x109/L BHaemoglobin ≥ 100 g/L ( transfusion allow ) PTotal bilirubin level ≤ 1.5 time upper institutional limit `` normal '' ( i.e . reference ) range PASAT PALAT ≤ 2.5 time upper institutional limit `` normal '' range , ≤5 time liver metastasis document PCreatinine ≤ 1.5 time upper institutional limit `` normal '' range 5 . Females childbearing potential use adequate contraception ( oral injectable contraceptive , hormone release intrauterine device ) throughout study period . 6 . Signed write informed consent . 1 . Ongoing infection major recent ongoing disease , accord investigator , pose unacceptable risk patient 2 . Known malignancy CNS 3 . Prior antitumour therapy within 4 week enrolment ( 6 week nitrosurea MitC ) . 4 . Pregnancy lactation 5 . Current participation interventional clinical trial 6 . Performance status &gt; ECOG 2 optimization analgesic 7 . Life expectancy le 3 month 8 . Contraindications investigational product , e.g . know suspected hypersensitivity . 9 . Lack suitability participation trial , reason , judge Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>